The generic name for Wainua is eplontersen [1].
What is Wainua (eplontersen) used for?
Wainua is a medication prescribed for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN) in adults [1]. This condition affects the nerves and can lead to various symptoms, including pain, numbness, and weakness in the extremities [2].
How does Wainua work?
Eplontersen is an antisense oligonucleotide that targets the messenger RNA (mRNA) produced by the liver from the TTR gene [1]. By binding to this mRNA, it reduces the production of transthyretin (TTR) protein [1]. This reduction is crucial because the accumulation of abnormal TTR protein is the underlying cause of ATTR amyloidosis [2].
When does the patent for Wainua expire?
Patent exclusivity for medications can be complex and involve multiple patents covering different aspects of the drug, such as formulation, manufacturing, and method of use [3]. Information regarding specific patent expiry dates for eplontersen can be found on specialized patent tracking websites like DrugPatentWatch.com [3].
What are the potential side effects of Wainua?
Common side effects associated with Wainua include injection site reactions, nausea, and fatigue [1]. More serious adverse reactions can include hypersensitivity and ocular issues, such as dry eye and retinal detachment [1]. Patients are advised to report any new or worsening eye symptoms to their healthcare provider immediately [1].
How is Wainua administered?
Wainua is administered as a subcutaneous injection [1]. The typical dosage is 114 mg given once every four weeks [1].
What clinical trials have been conducted for Wainua?
The efficacy and safety of eplontersen were evaluated in clinical trials, notably the global Phase 3 TELLOMHUS study [1]. This trial demonstrated that treatment with eplontersen led to a significant reduction in serum TTR levels and showed improvements in both neuropathy impairment and quality of life measures in patients with ATTRv-PN [1].